Last reviewed · How we verify
ENOXA®
Enoxa is a small molecule drug, but its exact mechanism of action is unknown.
Enoxa is a small molecule drug developed by Les Laboratoires des Médicaments Stériles, with its current ownership status remaining unchanged. Unfortunately, there is limited information available on its target, drug class, and approved indications. As a result, its commercial status, key safety considerations, and other essential details remain unknown. Further research is necessary to understand the specifics of Enoxap. The lack of available information makes it challenging to provide a comprehensive summary.
At a glance
| Generic name | ENOXA® |
|---|---|
| Sponsor | Les Laboratoires des Médicaments Stériles |
| Target | RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Unfortunately, there is not enough information available to explain how Enoxap works in simple terms. Typically, small molecule drugs work by interacting with specific biological targets, such as proteins or receptors, to produce a desired effect. However, without more information, it is impossible to provide a clear explanation of Enoxap's mechanism of action.
Approved indications
- Acute gonococcal cervicitis
- Acute gonococcal urethritis
- Gonorrhea
- Gonorrhea of pharynx
- Gonorrhea of rectum
- Urinary tract infectious disease
Common side effects
- Bleeding
- Anemia
- Thrombocytopenia
- Elevation of serum aminotransferase
- Diarrhea
- Nausea
- Ecchymosis
- Fever
- Edema
- Peripheral edema
- Dyspnea
- Confusion
Serious adverse events
- Major bleeding (Abdominal Surgery)
- Major bleeding (Colorectal Surgery)
- Major bleeding (Hip Replacement Surgery without Extended Prophylaxis)
- Major bleeding (Knee Replacement Surgery without Extended Prophylaxis)
- Major bleeding (Medical Patients during Acute Illness - 40mg daily)
- Major bleeding (Treatment of DVT and PE - 1.5mg/kg daily)
- Major bleeding (Treatment of DVT and PE - 1mg/kg q12h)
- Hemorrhage
Key clinical trials
- Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox® (PHASE4)
- Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENOXA® CI brief — competitive landscape report
- ENOXA® updates RSS · CI watch RSS
- Les Laboratoires des Médicaments Stériles portfolio CI